Document Detail


Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
MedLine Citation:
PMID:  25445207     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The identification of individuals with severe liver fibrosis among patients with chronic liver disease is of major importance when evaluating prognosis, potential risk for complications, and when deciding treatment strategies. Although percutaneous liver biopsy is still considered a "gold standard" for staging of liver fibrosis, attempts to find reliable noninvasive markers of liver fibrosis are frequent. Inflammation is essential for the progression of fibrosis. The urokinase plasminogen activator and its receptor have been associated with hepatic inflammation and fibrosis in mice. High serum concentrations of soluble urokinase plasminogen activator receptor (suPAR) are suggested to be involved in inflammation, tissue remodeling, and cancer metastasis. Here, we evaluated serum suPAR as a noninvasive test to detect liver fibrosis in 82 well-characterized patients with nonalcoholic fatty liver disease (NAFLD), and in 38 untreated patients with chronic hepatitis C virus (HCV) infection at the time of their first liver biopsy. suPAR levels were increased in chronic liver disease compared with blood donors (P < 0.001). Patients with HCV had higher suPAR concentrations than patients with NAFLD (P < 0.002). suPAR levels were associated with the severity of fibrosis, particularly in NAFLD, but did not correlate with inflammation. Regarding the performance in predicting severity of fibrosis, suPAR was essentially as good as other commonly used noninvasive fibrosis scoring systems. The results in HCV confirm previous observations. However, this is the first study to investigate suPAR as a biomarker in NAFLD, and the results indicate that suPAR may constitute a severity marker related to fibrosis and prognosis rather than reflecting inflammation.
Authors:
Christopher Sjöwall; Klara Martinsson; Kristina Cardell; Mattias Ekstedt; Stergios Kechagias
Related Documents :
12584317 - Persistent replication of hepatitis c virus replicons expressing the beta-lactamase rep...
25420817 - Co-infected hiv/hepatitis patients compared with chronic liver patients and healthy ind...
25283857 - Pretreatment and on-treatment indicators of virologic breakthrough of lamivudine therap...
17083037 - Possible compartmentalization of hepatitis c viral replication in the genital tract of ...
19465707 - Strategies for managing coinfection with hepatitis b virus and hiv.
24897817 - Isoniazid preventive therapy for tuberculosis in south africa: an assessment of the loc...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-5
Journal Detail:
Title:  Translational research : the journal of laboratory and clinical medicine     Volume:  -     ISSN:  1878-1810     ISO Abbreviation:  Transl Res     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  101280339     Medline TA:  Transl Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interferon regulatory factors: critical mediators of human lupus.
Next Document:  Applicability of estimating glomerular filtration rate equations in pediatric patients: comparison w...